Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $300000.0.

  • China Pharma Holdings' Cash & Equivalents fell 5825.74% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $300000.0, marking a year-over-year decrease of 5825.74%. This contributed to the annual value of $626879.0 for FY2024, which is 5597.26% down from last year.
  • Per China Pharma Holdings' latest filing, its Cash & Equivalents stood at $300000.0 for Q3 2025, which was down 5825.74% from $625032.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Cash & Equivalents ranged from a high of $4.9 million in Q4 2021 and a low of $300000.0 during Q3 2025
  • Moreover, its 5-year median value for Cash & Equivalents was $901910.0 (2023), whereas its average is $1.4 million.
  • Per our database at Business Quant, China Pharma Holdings' Cash & Equivalents skyrocketed by 59496.75% in 2022 and then tumbled by 6858.66% in 2023.
  • China Pharma Holdings' Cash & Equivalents (Quarter) stood at $4.9 million in 2021, then plummeted by 58.22% to $2.0 million in 2022, then decreased by 29.86% to $1.4 million in 2023, then plummeted by 55.97% to $626879.0 in 2024, then plummeted by 52.14% to $300000.0 in 2025.
  • Its last three reported values are $300000.0 in Q3 2025, $625032.0 for Q2 2025, and $412688.0 during Q1 2025.